中国实用眼科杂志
中國實用眼科雜誌
중국실용안과잡지
CHINESE JOURNAL OF PRACTICAL OPHTHALMOLOGY
2012年
2期
193-195
,共3页
范银波%肖云%张改丽%渠岚%顾永欣%张燕
範銀波%肖雲%張改麗%渠嵐%顧永訢%張燕
범은파%초운%장개려%거람%고영흔%장연
光动力疗法%中心性浆液性脉络膜视网膜病变%光学相干断层扣描%眼底荧光血管造影
光動力療法%中心性漿液性脈絡膜視網膜病變%光學相榦斷層釦描%眼底熒光血管造影
광동력요법%중심성장액성맥락막시망막병변%광학상간단층구묘%안저형광혈관조영
Photodynamic therapy%Central serous chorioretinopathy%Optical coherence tomography%Fundus fluorenscense angiography
目的 观察半剂量光动力疗法治疗中心性浆液性脉络膜视网膜病变的疗效及安全性.方法 2008年4月至2010年9月在门诊确诊的中心性浆液性脉络膜视网膜病变患者24例24只眼,其中男20例20只眼,女4例4只眼,年龄27~48岁,平均36.8岁,最佳矫正视力0.2~0.5,平均0.42,行半剂量光动力疗法治疗,随访按照术后l周、1月、3月、6月、9月进行,随访时间3~8月,平均4.8月,随访期间分别行裂隙灯眼底镜检查、最佳矫正视力、OCT及FFA检查,观察治疗的有效性和安全性.结果 术后l周,OCT显示4只眼视网膜下积液吸收,19只眼视网膜下积液部分吸收,1只眼视网膜下积液无明显变化;术后1月,OCT显示18只眼视网膜下积液吸收,5只眼视网膜下积液部分吸收,1只眼视网膜下积液无明显变化;FFA显示19只眼荧光渗漏消失,4只眼渗漏减轻,1只眼渗漏无明显变化.术后3月,OCT最示23只眼视网膜下积液吸收,1只眼视网膜下积液部分吸收;FFA显示23只眼荧光渗漏消失,1只眼渗漏减轻.对渗漏未完全消失眼再次行半剂量光动力疗法,1月后OCT显示视网膜下积液吸收,FFA显示荧光渗漏消失呈荧光着染.末次随访时最佳矫正视力0.5~1.0,提高2行以上者19只眼.结论 半剂量光动力疗法治疗中心性浆液性脉络膜视网膜病变疗效显著,安全.
目的 觀察半劑量光動力療法治療中心性漿液性脈絡膜視網膜病變的療效及安全性.方法 2008年4月至2010年9月在門診確診的中心性漿液性脈絡膜視網膜病變患者24例24隻眼,其中男20例20隻眼,女4例4隻眼,年齡27~48歲,平均36.8歲,最佳矯正視力0.2~0.5,平均0.42,行半劑量光動力療法治療,隨訪按照術後l週、1月、3月、6月、9月進行,隨訪時間3~8月,平均4.8月,隨訪期間分彆行裂隙燈眼底鏡檢查、最佳矯正視力、OCT及FFA檢查,觀察治療的有效性和安全性.結果 術後l週,OCT顯示4隻眼視網膜下積液吸收,19隻眼視網膜下積液部分吸收,1隻眼視網膜下積液無明顯變化;術後1月,OCT顯示18隻眼視網膜下積液吸收,5隻眼視網膜下積液部分吸收,1隻眼視網膜下積液無明顯變化;FFA顯示19隻眼熒光滲漏消失,4隻眼滲漏減輕,1隻眼滲漏無明顯變化.術後3月,OCT最示23隻眼視網膜下積液吸收,1隻眼視網膜下積液部分吸收;FFA顯示23隻眼熒光滲漏消失,1隻眼滲漏減輕.對滲漏未完全消失眼再次行半劑量光動力療法,1月後OCT顯示視網膜下積液吸收,FFA顯示熒光滲漏消失呈熒光著染.末次隨訪時最佳矯正視力0.5~1.0,提高2行以上者19隻眼.結論 半劑量光動力療法治療中心性漿液性脈絡膜視網膜病變療效顯著,安全.
목적 관찰반제량광동력요법치료중심성장액성맥락막시망막병변적료효급안전성.방법 2008년4월지2010년9월재문진학진적중심성장액성맥락막시망막병변환자24례24지안,기중남20례20지안,녀4례4지안,년령27~48세,평균36.8세,최가교정시력0.2~0.5,평균0.42,행반제량광동력요법치료,수방안조술후l주、1월、3월、6월、9월진행,수방시간3~8월,평균4.8월,수방기간분별행렬극등안저경검사、최가교정시력、OCT급FFA검사,관찰치료적유효성화안전성.결과 술후l주,OCT현시4지안시망막하적액흡수,19지안시망막하적액부분흡수,1지안시망막하적액무명현변화;술후1월,OCT현시18지안시망막하적액흡수,5지안시망막하적액부분흡수,1지안시망막하적액무명현변화;FFA현시19지안형광삼루소실,4지안삼루감경,1지안삼루무명현변화.술후3월,OCT최시23지안시망막하적액흡수,1지안시망막하적액부분흡수;FFA현시23지안형광삼루소실,1지안삼루감경.대삼루미완전소실안재차행반제량광동력요법,1월후OCT현시시망막하적액흡수,FFA현시형광삼루소실정형광착염.말차수방시최가교정시력0.5~1.0,제고2행이상자19지안.결론 반제량광동력요법치료중심성장액성맥락막시망막병변료효현저,안전.
Objective To observe the effect and security of photodynamic therapy with half-dose verteporfin for central serous chorioretinopathy (CSC). Methods Twenty-four eyes of 24 patients diagnosed CSC by fundus examination,FFA and OCT.Photodynamic therapy with half-dose verteporfin were employed on leakage position according to ICGA.Laser treatment at a light intensity of 600mw/m2 and dose of 50J/cm2 and duration of 83 seconds were performed 15 minutes after verteporfin was infused.Patients were followed up for 3-9 months with visual acuity measurements,dilated ophthalmoscopy,FFA and OCT to observe the effect and security of treatment. Results One week after PDT,OCT showed that subretinal fluid of 4 eyes absorbed absolutely,of 19 eyes partly and 1 eye without any change.One month after PDT,OCT showed that subretinal fluid of 18 eyes absorbed absolutely,of 5 eyes partly and 1 eye without any change,FFA showed that fluorescence leakage of 19 eyes disappeared,of 4 eyes lessened and 1 eye without any change.Three months after PDT,OCT showed that subretinal fluid of 23 eyes absorbed absolutely,of 1 eye lessened.The one eye with fluorescence leaking accepted the second time PDT,one month after PDT,the subretinal fluid absorbed absolutely by OCT and leakage disappeared by FFA.The visual acuity of last follow up was 0.5-1.0,of 19 eyes elevated two rows. Conclusions It is effective and secure that photodynamic therapy with half-dose verteporfin treat central serous chorioretinopathy.